Concise review

Preleukemic stem cells: Molecular biology and clinical implications of the Precursors to leukemia stem cells

Ashley Pandolfi, Laura Barreyro, Ulrich G. Steidl

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Recent experimental evidence has shown that acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from transformed immature hematopoietic cells following the accumulation of multiple stepwise genetic and epigenetic changes in hematopoietic stem cells and committed progenitors. The series of transforming events initially gives rise to preleukemic stem cells (pre-LSC), preceding the formation of fully transformed leukemia stem cells (LSC). Despite the established use of poly-chemotherapy, relapse continues to be the most common cause of death in AML and MDS. The therapeutic elimination of all LSC, as well as pre-LSC, which provide a silent reservoir for the re-formation of LSC, will be essential for achieving lasting cures. Conventional sequencing and nextgeneration genome sequencing have allowed us to describe many of the recurrent mutations in the bulk cell populations in AML and MDS, and recent work has also focused on identifying the initial molecular changes contributing to leukemogenesis. Here we review recent and ongoing advances in understanding the roles of pre-LSC, and the aberrations that lead to pre-LSC formation and subsequent LSC transformation.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalStem cells translational medicine
Volume2
Issue number2
DOIs
StatePublished - 2013

Fingerprint

Cell Biology
Molecular Biology
Leukemia
Stem Cells
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Hematopoietic Stem Cells
Epigenomics
Cause of Death
Genome
Recurrence
Drug Therapy
Mutation
Population

Keywords

  • Acute myelogenous leukemia
  • Cancer stem cells
  • Hematopoietic stem cells
  • Stem/progenitor cell

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Concise review : Preleukemic stem cells: Molecular biology and clinical implications of the Precursors to leukemia stem cells. / Pandolfi, Ashley; Barreyro, Laura; Steidl, Ulrich G.

In: Stem cells translational medicine, Vol. 2, No. 2, 2013, p. 143-150.

Research output: Contribution to journalArticle

@article{b435e6e2c7c240b0aa05373f644d23e8,
title = "Concise review: Preleukemic stem cells: Molecular biology and clinical implications of the Precursors to leukemia stem cells",
abstract = "Recent experimental evidence has shown that acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from transformed immature hematopoietic cells following the accumulation of multiple stepwise genetic and epigenetic changes in hematopoietic stem cells and committed progenitors. The series of transforming events initially gives rise to preleukemic stem cells (pre-LSC), preceding the formation of fully transformed leukemia stem cells (LSC). Despite the established use of poly-chemotherapy, relapse continues to be the most common cause of death in AML and MDS. The therapeutic elimination of all LSC, as well as pre-LSC, which provide a silent reservoir for the re-formation of LSC, will be essential for achieving lasting cures. Conventional sequencing and nextgeneration genome sequencing have allowed us to describe many of the recurrent mutations in the bulk cell populations in AML and MDS, and recent work has also focused on identifying the initial molecular changes contributing to leukemogenesis. Here we review recent and ongoing advances in understanding the roles of pre-LSC, and the aberrations that lead to pre-LSC formation and subsequent LSC transformation.",
keywords = "Acute myelogenous leukemia, Cancer stem cells, Hematopoietic stem cells, Stem/progenitor cell",
author = "Ashley Pandolfi and Laura Barreyro and Steidl, {Ulrich G.}",
year = "2013",
doi = "10.5966/sctm.2012-0109",
language = "English (US)",
volume = "2",
pages = "143--150",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Concise review

T2 - Preleukemic stem cells: Molecular biology and clinical implications of the Precursors to leukemia stem cells

AU - Pandolfi, Ashley

AU - Barreyro, Laura

AU - Steidl, Ulrich G.

PY - 2013

Y1 - 2013

N2 - Recent experimental evidence has shown that acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from transformed immature hematopoietic cells following the accumulation of multiple stepwise genetic and epigenetic changes in hematopoietic stem cells and committed progenitors. The series of transforming events initially gives rise to preleukemic stem cells (pre-LSC), preceding the formation of fully transformed leukemia stem cells (LSC). Despite the established use of poly-chemotherapy, relapse continues to be the most common cause of death in AML and MDS. The therapeutic elimination of all LSC, as well as pre-LSC, which provide a silent reservoir for the re-formation of LSC, will be essential for achieving lasting cures. Conventional sequencing and nextgeneration genome sequencing have allowed us to describe many of the recurrent mutations in the bulk cell populations in AML and MDS, and recent work has also focused on identifying the initial molecular changes contributing to leukemogenesis. Here we review recent and ongoing advances in understanding the roles of pre-LSC, and the aberrations that lead to pre-LSC formation and subsequent LSC transformation.

AB - Recent experimental evidence has shown that acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from transformed immature hematopoietic cells following the accumulation of multiple stepwise genetic and epigenetic changes in hematopoietic stem cells and committed progenitors. The series of transforming events initially gives rise to preleukemic stem cells (pre-LSC), preceding the formation of fully transformed leukemia stem cells (LSC). Despite the established use of poly-chemotherapy, relapse continues to be the most common cause of death in AML and MDS. The therapeutic elimination of all LSC, as well as pre-LSC, which provide a silent reservoir for the re-formation of LSC, will be essential for achieving lasting cures. Conventional sequencing and nextgeneration genome sequencing have allowed us to describe many of the recurrent mutations in the bulk cell populations in AML and MDS, and recent work has also focused on identifying the initial molecular changes contributing to leukemogenesis. Here we review recent and ongoing advances in understanding the roles of pre-LSC, and the aberrations that lead to pre-LSC formation and subsequent LSC transformation.

KW - Acute myelogenous leukemia

KW - Cancer stem cells

KW - Hematopoietic stem cells

KW - Stem/progenitor cell

UR - http://www.scopus.com/inward/record.url?scp=84876511698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876511698&partnerID=8YFLogxK

U2 - 10.5966/sctm.2012-0109

DO - 10.5966/sctm.2012-0109

M3 - Article

VL - 2

SP - 143

EP - 150

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 2

ER -